Abstract
Whereas the detection of antiphospholipid autoantibodies (aPL) in COVID-19 is of increasing interest, their role is still unclear. We analyzed a large aPL panel in 157 patients with COVID-19 according to the disease severity. We also investigated a potential association between aPL and extracellular DNA (exDNA, n = 85) or circulating markers of neutrophil extracellular traps (NET) such as citrullinated histones H3 (CitH3, n = 49). A total of 157 sera of patients infected by SARS-CoV-2 were collected. A large aPL panel including lupus anticoagulant, anti-cardiolipin and anti-beta-2 glycoprotein I (IgG, IgM and IgA), anti-phosphatidylethanolamine IgA, anti-prothrombin (IgG and IgM) was retrospectively analyzed according to the disease severity. We found a total aPL prevalence of 54.8% with almost half of the cases having aCL IgG. Within an extended panel of aPL, only aCL IgG were associated with COVID-19 severity. Additionally, severe patients displayed higher CitH3 levels than mild patients. Interestingly, we highlighted a significant association between the levels of aCL IgG and exDNA only in aCL positive patients with severe disease. In conclusion, we showed a significant link between aPL, namely aCL IgG, and circulating exDNA in patients with severe form of COVID-19, that could exacerbate the thrombo-inflammatory state related to disease severity.
【초록키워드】 COVID-19, SARS-CoV-2, IgG, IgM, Neutrophil extracellular traps, severity, disease severity, neutrophil, COVID-19 severity, Prevalence, IgA, sera, Patient, Neutrophil extracellular trap, glycoprotein, Severe patient, Lupus, prothrombin, mild patients, lupus anticoagulant, association, marker, Anticoagulant, severe disease, autoantibody, IgG and IgM, severe patients, positive patients, extracellular DNA, circulating, NET, citrullinated histones, analyzed, collected, investigated, the disease, positive patient, exacerbate, citrullinated histone, patients with COVID-19, with COVID-19, 【제목키워드】 IgG, severe COVID-19, autoantibody, extracellular DNA, circulating,